Personally I'd rather see them diluting to making poor partnerships where the partner will own most of the revenue flow. We compare with SGEN and they build on far more dilution, and better partnerships. IMGN has carefully guarded its shares, then monetize drugs which could have developed major revenue streams. The least I want from anything IMGN developed is maintaining 100% of U.S. ownership. If they partner for elsewhere I'm fine with that, but I don't want anyone even taking $1 of anything being sold here in the U.S.